PURPOSE: To evaluate macular focal cone ERG (fERG) as a tool for reliable and early detection of central retinal function decay in cone-rod dystrophy (CRD). METHODS: A retrospective study of the time course of fERG amplitude and its relation to visual acuity alterations was performed in 47 CRD patients followed yearly for 6.0 ± 3.1 years. Macular focal cone ERG was evoked by a flickering uniform red field overlaying the central 18° of visual field. RESULTS: Macular focal cone ERG follow-up allowed a clear-cut identification of CRD patients as stationary or progressive, in agreement with visual acuity follow-up. In all progressive patients, fERG declined whenever visual acuity declined, and--in 50% of the cases--fERG loss anticipated acuity loss of several years. CONCLUSIONS: Macular focal cone ERG represents a sensitive assay to detect, categorize, and follow the progression of central retinal dysfunction in CRD. Its use as a diagnostic tool in CRD may help anticipate, for an individual patient, the likelihood and rate of further disease progression before visual acuity loss has occurred.
PURPOSE: To evaluate macular focal cone ERG (fERG) as a tool for reliable and early detection of central retinal function decay in cone-rod dystrophy (CRD). METHODS: A retrospective study of the time course of fERG amplitude and its relation to visual acuity alterations was performed in 47 CRDpatients followed yearly for 6.0 ± 3.1 years. Macular focal cone ERG was evoked by a flickering uniform red field overlaying the central 18° of visual field. RESULTS: Macular focal cone ERG follow-up allowed a clear-cut identification of CRDpatients as stationary or progressive, in agreement with visual acuity follow-up. In all progressive patients, fERG declined whenever visual acuity declined, and--in 50% of the cases--fERG loss anticipated acuity loss of several years. CONCLUSIONS: Macular focal cone ERG represents a sensitive assay to detect, categorize, and follow the progression of central retinal dysfunction in CRD. Its use as a diagnostic tool in CRD may help anticipate, for an individual patient, the likelihood and rate of further disease progression before visual acuity loss has occurred.
Authors: Tjaša Krašovec; Marija Volk; Maja Šuštar Habjan; Marko Hawlina; Nataša Vidović Valentinčič; Ana Fakin Journal: Int J Mol Sci Date: 2022-07-02 Impact factor: 6.208
Authors: Maria C Savastano; Benedetto Falsini; Grazia M Cozzupoli; Alfonso Savastano; Gloria Gambini; Umberto De Vico; Angelo M Minnella; Giorgio Placidi; Marco Piccardi; Stanislao Rizzo Journal: J Clin Med Date: 2020-09-15 Impact factor: 4.241